Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03666819

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Phase II Trial of CO2RE Laser for Patients With Stage 0-III Hormone Receptor-Positive Breast Cancer on Aromatase Inhibitors With Vulvovaginal Atrophy

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well carbon dioxide fractional (CO2RE) laser works in treating participants with stage 0-III hormone receptor-positive breast cancer with vulvovaginal atrophy associated with dryness, inflammation or thinning of the epithelial lining of the vulva and vagina. CO2RE laser is a device that delivers controlled CO2 energy to the vaginal tissue and may help treat vaginal symptoms such as itching, burning, painful sexual intercourse, thickened or thin skin of the vulva, and stinging.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the reduction in Vulvovaginal Symptom Questionnaire (VSQ) score at 3-month follow up after CO2RE laser treatment. SECONDARY OBJECTIVES: I. To evaluate the reduction in VSQ score after CO2RE laser treatment 6-month follow-up and 12-month follow-up. II. To evaluate Female Sexual Function Index (FSFI) score before and after treatment with CO2RE laser. III. To evaluate Urogenital Distress Inventory (UDI) 6 score before and after treatment with CO2RE laser. IV. To evaluate vaginal health index score and vaginal caliber before and after treatment with CO2RE laser. V. To evaluate discomfort and pain during CO2RE laser treatment using the visual analog scale. VI. To evaluate treatment satisfaction after CO2RE laser treatment using 5-point Likert scale. VII. To evaluate adherence to aromatase inhibitor at 6 and 12 months after CO2RE laser treatment. EXPLORATORY OBJECTIVES: I. To assess the change in the vaginal cytology using vaginal maturation index at baseline and during follow-up. II. To assess serum estradiol level at baseline and after CO2RE laser treatment. OUTLINE: Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 3, 6, and 12 months.

Conditions

Interventions

TypeNameDescription
DEVICECarbon Dioxide Fractional LaserUndergo CO2RE laser therapy
OTHERQuestionnaire AdministrationAncillary studies

Timeline

Start date
2018-09-10
Primary completion
2021-09-10
Completion
2021-09-10
First posted
2018-09-12
Last updated
2023-01-06

Regulatory

Source: ClinicalTrials.gov record NCT03666819. Inclusion in this directory is not an endorsement.